BriaCell Therapeutics (OTCQB:BCTXF) has filed a provisional patent application with the USPTO, entitled “MULTI-VALENT DECOY RECEPTORS FOR DIAGNOSIS AND/OR TREATMENT OF CORONAVIRUS INFECTION”.
The application outlines compositions and methods of developing novel multi-valent decoy receptors for diagnosis and treatment of coronavirus infection and seeks protection for the design of new therapeutics and methods for their use.
Multi-valent constructs are believed to have both therapeutic and diagnostic potential.
BriaCell has recently filed three other provisional patent applications related to treatments for coronavirus, including: (1) genetically engineered whole-cell immunotherapy (2) antibody-based treatment; and (3) antigen-based induction of immune response.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.